In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

MacroGenics grants Servier an option to license MGA271 for cancer; deal ends

Executive Summary

MacroGenics Inc. (therapeutics for autoimmune and infectious diseases and cancer) has granted Servier SA an option to license exclusive worldwide rights (excluding the US, Canada, Mexico, Japan, Korea, and India) to MGA271, in Phase I for solid tumors.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register